Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) Other Non Operating Income (2021 - 2025)

InMed Pharmaceuticals' Other Non Operating Income history spans 5 years, with the latest figure at $18136.0 for Q4 2025.

  • For Q4 2025, Other Non Operating Income rose 137.98% year-over-year to $18136.0; the TTM value through Dec 2025 reached -$38886.0, up 61.8%, while the annual FY2025 figure was -$28471.0, 54.02% up from the prior year.
  • Other Non Operating Income reached $18136.0 in Q4 2025 per INM's latest filing, up from -$56994.0 in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $59896.0 in Q4 2023 to a low of -$96791.0 in Q3 2022.
  • Average Other Non Operating Income over 5 years is -$16387.6, with a median of -$12449.0 recorded in 2023.
  • Peak YoY movement for Other Non Operating Income: skyrocketed 573.0% in 2022, then plummeted 1662.02% in 2024.
  • A 5-year view of Other Non Operating Income shows it stood at $3007.0 in 2021, then surged by 573.0% to $20237.0 in 2022, then soared by 195.97% to $59896.0 in 2023, then crashed by 179.73% to -$47753.0 in 2024, then soared by 137.98% to $18136.0 in 2025.
  • Per Business Quant, the three most recent readings for INM's Other Non Operating Income are $18136.0 (Q4 2025), -$56994.0 (Q3 2025), and $22137.0 (Q2 2025).